A news article about a medtech company’s newly approved implant therapy entering the U.S. market, outlining planned commercial rollout and launch strategy.
Key Takeaways
- Approval allows Implantica to begin commercial launch activities in the United States
- It means that we can now bring RefluxStop® to the United States
- RefluxStop® already has several years of commercial experience in Europe